Evidence map›Paper›PMID 41974822›Full record

ArticleNPJ digital medicine2026

Soft multiclass feature augmented deep learning to predict tumor origins using cytology or histology whole slide images.

Ching-Wei Wang, Po-Jen Lai, Tzu-Chiao Chu, Tzu-Kang Wu, Chih-Hsuan Liang, Tai-Kuang Chao

Abstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ching-Wei WangGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei, Taiwan, ROC. cweiwang@mail.ntust.edu.tw.
Po-Jen LaiGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei, Taiwan, ROC.
Tzu-Chiao ChuGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei, Taiwan, ROC.
Tzu-Kang WuGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei, Taiwan, ROC.
Chih-Hsuan LiangGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei, Taiwan, ROC.
Tai-Kuang ChaoDepartment of Pathology, Tri-Service General Hospital, Taipei, Taiwan, ROC. chaotai.kuang@msa.hinet.net.

Funding

National Science and Technology Council NSTC 113-2222-E-011-003-MY3National Science and Technology Council NSTC 114-2221-E-016-001National Taiwan University of Science and Technology - Tri-Service General Hospital NTUST-TSGH-114-03Tri-Service General Hospital TSGH-A-113002
6 · The paper itself

Abstract

Tailoring cancer treatment to the primary tumor site is essential for optimal outcomes, yet identifying the source of metastasis remains a significant clinical challenge. The primary tumor location influences not only the choice of treatment but also its delivery method, potential side effects and overall prognosis. Cancer of unknown primary (CUP) persists despite comprehensive diagnostic evaluations. We present the first fast, low-cost deep learning based cancer screening approach, i.e. a new data efficient soft multiclass feature augmentation deep learning, to identify the primary origin of malignant cells directly from whole slide images (WSIs) of cytological smears (CS), cell blocks (CB) or histopathology slides. Our framework was evaluated across three datasets: a multi-center histopathology collection of 69 sites (1,196 WSIs), a CS dataset (260 WSIs), and a CB dataset (129 WSIs). The proposed method achieved excellent accuracy, outperforming four state-of-the-art methods in identifying common metastatic origins. These findings demonstrate the potential of this deep learning tool to advance precision oncology by rapidly guiding clinicians toward appropriate, site-specific cancer treatments.

Identifiers

PMID41974822
PMCPMC13265786

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.